SLC5A2 and hydrops fetalis: Subsequently, SGLT2 inhibitors, initially developed as antihyperglycemic agents, have shown compelling cardiovascular benefits independent of glycemic status, with large randomized controlled trials like Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) [6] and Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction (EMPEROR-Reduced) [7] highlighting their robust role in improving clinical outcomes in HFrEF patients.